[ad_1]
Announcement of the results of an extraordinary meeting of the safety committee
“There is no general link with the risk of thrombosis.
There is a very rare chance that a blood clot will form. “
AstraZeneca vaccine. Reuters Yonhap News
The European Medicines Agency (EMA) announced that the benefits of the COVID-19 vaccine developed jointly by the multinational pharmaceutical company AstraZeneca and the University of Oxford in the United Kingdom outweigh the risk. The European Medicines Agency held an extraordinary meeting of the Safety Committee on the 18th and announced that it had no general link between the Astrazeca vaccine and the increased risk of blood clotting thrombosis. The European Medicines Agency said the benefits of receiving the AstraZeneca vaccine still outweigh the risk of side effects and there is no evidence that there is a problem with the specific manufacturing site of the AstraZeneca vaccine. However, the European Medicines Agency said that “it may be related to a very rare blood clot related to platelet depletion. The European Medicines Agency is the agency responsible for the evaluation and approval of medicines and vaccines in the European Union. (EU) European Medicines Agency Commissioner Emma Cook said “the link” between the rare blood clot and the AstraZeneca vaccine cannot be completely ruled out, the news agency said. “Our scientific position is that this vaccine is a safe and effective option to protect citizens from COVID-19. This (AstraZeneca vaccine) has been shown to be at least 60% immune in clinical trials. And, indeed, in practice (the inoculation) showed that the immunological effect was greater than in clinical trials. ”On the 7th, the Austrian health authorities stopped vaccinating the company’s vaccine, claiming that two members of the medical staff died due to trauma. Blood clotting disorders after vaccination with the AstraZeneca vaccine. The inoculation was interrupted by the amount of water. The news agency said the announcement by the European Medicines Agency paved the way for European countries that stopped vaccinating AstraZeneca to resume immunization. The UK Medicines and Health Care Products Regulatory Agency (MHRA) also announced that there was no evidence that the AstraZeneca vaccine caused blood clots. However, the UK Medicines and Health Products Regulatory Authority also added: “5 cases of cerebral thrombosis, a very rare and specific type of platelet-depleted cerebral thrombosis, have been reported and are under further investigation. By Jo Ki-won, Staff Reporter
[ad_2]
